title: [Timing of UFT administration combined with surgical operation in pulmonary metastasis of rat mammary carcinoma].
abstract: We investigated the effective timing of UFT administration combined with surgical operation for inhibiting pulmonary metastasis of spontaneously developed mammary carcinoma (SST-2) which produces 100% pulmonary metastasis in syngeneic rats after s.c. transplantation. Rats (5 rats per group) were inoculated s.c. with 1 X 10(6) SST-2 cells and administered orally with UFT (15, 30 and 60 mg/kg/day) starting 21 days after the tumor inoculation for 2 weeks. UFT at the dose of 30 mg/kg/day was found to be most effective in inhibiting pulmonary metastasis in SHR rats without any noticeable side effects. The rats inoculated s.c. with 5 X 10(4) SST-2 cells were divided into 3 groups: The 1st group was given oral administration of UFT (30 mg/kg/day) starting 7 days before surgical excision of the primary tumor for 2 weeks; 2nd group was treated with UFT starting one day after surgical operation for 2 weeks; and 3rd group was treated with UFT starting 7 days after surgical operation for 2 weeks. The number of lung colonies and survival time were compared among these 3 groups. The results clearly showed that combination of UFT and surgical operation was most effective on the 1st group when compared with the other two groups. UFT therapy, therefore, should be started prior to surgical operation for inhibiting cancer metastasis.
authors.affiliation: Laboratory of Pathology, University School of Medicine, Sapporo, Japan.
authors.forename: X B
authors.initials: XB
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Hamada
authors.forename: N
authors.initials: N
authors.lastname: Takeichi
authors.forename: M
authors.initials: M
authors.lastname: Hosokawa
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D008175:Lung Neoplasms / Q000188:drug therapy / Q000517:prevention & control / Q000556:secondary*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D051381:Rats; D011918:Rats, Inbred SHR; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil